Volume 12, Issue 2 (Int J Mol Cell Med 2023)                   Int J Mol Cell Med 2023, 12(2): 100-107 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yesudas R, Thirumalairaj V K, Durairaj G, Chacko A, Shanmugaasokan L, Gunasekaran S. Stigmasterol- an Acetylcholinesterase Inhibitor from Phormidium retzii with relevance to Alzheimer’s disease Therapy. Int J Mol Cell Med 2023; 12 (2) :100-107
URL: http://ijmcmed.org/article-1-2103-en.html
1- CMS College of Science and Commerce, Chinnavedampatti (PO), Coimbatore, Tamil Nadu, India. , drrincyyesudas@gmail.com
2- CMS College of Science and Commerce, Chinnavedampatti (PO), Coimbatore, Tamil Nadu, India.
3- Dr. N.G.P. Arts and Science College, Coimbatore, Tamil Nadu, India.
4- CAS in Marine Biology, Annamalai University, Chidambaram, Tamil Nadu, India.
Abstract:   (1053 Views)
This study observed in vitro screening, purification and identification of cholinesterase inhibitors from the microalgae Phormidium retzii. Mixed microalgal culture was screened from freshwater samples for Phormidium sp. Single colony was purified and authenticated as P. retzii. Acetylcholinesterase (AChE) enzyme was purified from hRBC ghost. Sequential extraction of P. retzii was performed using organic solvents. Cholinesterase enzyme activity and its inhibition by various extracts were then tested. The active fractions were then subjected to partial purification and characterization. Petroleum ether extract of P. retzii showed maximum inhibition of 68.6 % against AChE while other solvent extracts showed no inhibition. Seven fractions were obtained from the active extract using thin layer chromatography. Among which fraction no. 5 showed maximum inhibition of 86.37 % towards AChE. Fraction no. 5 when subjected to GC-MS led to determination of the active principle as stigmasterol. The maximum inhibition of stigmasterol (0.45µM) was 81.2±0.08% with IC50 value of 0.214. Stigmasterol from P. retzii inhibited AChE projecting itself as safer drug for Alzheimer’s disease with minimal side effects.
Full-Text [PDF 433 kb]   (486 Downloads)    
Type of Study: Original Article | Subject: Other
Received: 2023/02/8 | Accepted: 2023/11/12 | Published: 2023/12/16

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | International Journal of Molecular and Cellular Medicine (IJMCM)

Designed & Developed by : Yektaweb